Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age

Zaman, Khalequ; Sack, David A.; Yunus, Muhammad; Arifeen, Shams El; Podder, Goutam; Azim, Tasnim; Luby, Stephen P.; Breiman, Robert F.; Neuzil, Kathleen M.; Datta, Sanjoy; Delem, Andrée; Suryakiran, P.V.; Bock, Hans L.

doi:10.1016/j.vaccine.2008.12.059

Cited by 105 publications

(67 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, there has been evidence from earlier studies in South Africa and Bangladesh which indicates a lack of interference between RIX4414 and OPV in terms of immunogenicity of both vaccines even when the two vaccines were co-administered. 11,12 In our study, we found that at the age of enrolment (eight weeks), about a quarter of the infants were already seropositive for anti-rotavirus IgA. Similarly high initial seropositivity rates (in the absence of prior vaccination) have been observed in South Asia 5.5% in RIX4414 group and 6.6% in placebo group.…”

Section: Introductionsupporting

confidence: 70%

“…9,11,12 However, higher seroconversion rates have been observed in more developed Asian settings, including infants of Indian ethnicity. 13 While the effect of socio-economic status on the immunogenicity of the vaccine is not fully determined yet, data from a wide range of countries suggest that lower socio-economic status may be associated with lower seroconversion rate, but not necessarily a lower efficacy.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Immunogenicity, reactogenicity and safety of human rotavirus vaccine (RIX4414) in Indian infants

Narang¹,

Bose²,

Pandit³

et al. 2009

Human Vaccines

View full text Add to dashboard Cite

Section: Introductionsupporting

confidence: 70%

Section: Introductionmentioning

confidence: 99%

Immunogenicity, reactogenicity and safety of human rotavirus vaccine (RIX4414) in Indian infants

Narang¹,

Bose²,

Pandit³

et al. 2009

Human Vaccines

View full text Add to dashboard Cite

“…Rotavirus replication in vitro is impaired by the presence of an enterovirus, but the converse is not true [132]. Consistent with this, vaccine co-administration does not appear to inhibit the immunogenicity of OPV [133]. The situation for rotavirus vaccines may be more complex -while the first dose of either Rotarix or RotaTeq has generally proven to be less immunogenic when administered with OPV than without, after a full course antibody titers are similar in these groups [134].…”

Section: Enteric Infectionsmentioning

confidence: 78%

“…[65], [98], [108], [135], [171], [196] [67], [133][134][135], [198][199][200][201] [8], [181], [182], [201], [203], [204] [28], [92], [93], [128], [131], [137], [138], [140], [130], [131], [157], [202] [ [43][44][45], [49], [61][62][63][64][65][66][67][68][69][70], [197] [ [155][156][157] [28], [98], [170][171][172]…”

Section: Conclusion and Future Perspectiveunclassified

Causes of Impaired Oral Vaccine Efficacy in Developing Countries

et al. 2017

View full text Add to dashboard Cite

Oral vaccines are less immunogenic when given to infants in low-income compared with high-income countries, limiting their potential public health impact. Here, we review factors that might contribute to this phenomenon, including transplacental antibodies, breastfeeding, histo blood group antigens, enteric pathogens, malnutrition, microbiota dysbiosis and environmental enteropathy. We highlight several clear risk factors for vaccine failure, such as the inhibitory effect of enteroviruses on oral poliovirus vaccine. We also highlight the ambiguous and at times contradictory nature of the available evidence, which undoubtedly reflects the complex and interconnected nature of the factors involved. Mechanisms responsible for diminished immunogenicity may be specific to each oral vaccine. Interventions aiming to improve vaccine performance may need to reflect the diversity of these mechanisms. Enteric pathogens are a substantial threat to public health. This threat takes many forms, from the toxin-producing bacteria (e.g., Vibrio cholerae) and flagellated protozoa (e.g., Giardia lamblia) that colonize the mucosal surface of the small intestine to the enteroviruses that are capable of spreading via the bloodstream to the CNS, causing acute flaccid paralysis (e.g., poliovirus). Each year, enteric pathogens cause hundreds of millions of cases of diarrhea and approximately 800,000 deaths, the vast majority of which occur among children in low-income countries [1]. The most common causes of childhood diarrheal morbidity include rotavirus, Cryptosporidium, enterotoxigenic Escherichia coli and Shigella [2].Vaccines against enteric pathogens are important tools for mitigating this disease burden. Oral vaccines offer several distinct benefits compared with parenteral vaccines. They can be produced in large quantities at relatively low cost, are easy to administer and have the capacity to induce local immunity in the intestinal mucosa, thereby protecting vaccinated individuals against subsequent infection and -by blocking onward transmission -enhancing herd immunity [3,4]. Currently licensed oral vaccines include live-attenuated poliovirus vaccines containing one, two or three serotypes, live-attenuated rotavirus vaccines (Rotarix R , RotaTeq R , Lanzhou lamb rotavirus vaccine [China only] and Rotavac R [India only]), live-attenuated cholera vaccine (CVD 103-HgR or Vaxchora TM ), inactivated cholera vaccines (Dukoral R and Shanchol R ) and live-attenuated typhoid vaccine (Ty21a). Other oral vaccines are in development, including those against Shigella, enterotoxigenic E. coli, Campylobacter and Clostridium difficile, as well as several novel rotavirus vaccine candidates (including the human neonatal vaccine RV3-BB [5] and an oral bovine pentavalent vaccine [6]).Yet oral vaccines have an Achilles' heel -their immunogenicity and efficacy is impaired in low-income countries that experience the greatest burden of enteric disease (Box 1). For example, Rotarix has a 1-year protective efficacy against severe rotavirus-associated gas...

show abstract

“…Since RV and PV share similar transmission routes, simultaneous prevention of RV and PV has great importance for optimal utilization of the limited resources in developing countries. Some studies showed that PV vaccines were evaluated in co-administration with oral RV vaccines according to the Expanded Program on Immunization (EPI) schedule were proved effective and safe (Steele et al, 2010;Zaman et al, 2009).…”

Section: Introductionmentioning

confidence: 99%

Immunogenicity and antigenicity of a recombinant chimeric protein containing epitopes of poliovirus type 1

Xx¹,

Wang²,

Wy³

et al. 2016

View full text Add to dashboard Cite

Summary. -To design a vaccine that simultaneously prevents both rotavirus (RV) and poliovirus (PV), a PV type 1 (PV1) chimeric protein using RV VP6 as a vector (VP6F) was constructed, expressed in Escherichia coli expression system and characterized by SDS-PAGE, Western blot, immunofluorescence assay and neutralization test. The results showed that the chimeric protein reacted with anti-VP6F and anti-PV1 antibodies and elicited production of serum antibodies against the chimeric protein in guinea pigs. Antibodies against the chimeric protein neutralized RV Wa and PV1 infection in vitro. The results provided a relevant possibility of developing novel approaches in the rational design of vaccines effective against both RV and PV.Keywords: chimeric protein; neutralizing activity; rotavirus; poliovirus epitope * Corresponding author. E-mail: chenyd@imbcams.com.cn; phone: +86-871-68335402. Abbreviations: CPE = cytopathic effect; PV = poliovirus; RV = rotavirus; TCID 50 = 50% tissue culture infectivity doses

show abstract

Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age

Cited by 105 publications

References 14 publications

Immunogenicity, reactogenicity and safety of human rotavirus vaccine (RIX4414) in Indian infants

Immunogenicity, reactogenicity and safety of human rotavirus vaccine (RIX4414) in Indian infants

Causes of Impaired Oral Vaccine Efficacy in Developing Countries

Immunogenicity and antigenicity of a recombinant chimeric protein containing epitopes of poliovirus type 1

Contact Info

Product

Resources

About